Fisher & Paykel HealthcareFRA:FPLB +2.72%91 EBITDA Margin % is 36.12% as of Mar. 2026, which is 8% above its 10-year median of 33.48. GuruFocus rates FRA:FPLB with a GF Score™ of 91/100 and a GF Value™ of €21.23. The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks better than 93.75% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Fisher & Paykel Healthcare EBITDA Margin % Related Terms
Fisher & Paykel Healthcare EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:FPLB vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (FRA:FPLB) has a EBITDA Margin % of 36.12% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fisher & Paykel Healthcare and its competitors. This is near median its historical median of 33.48. Over the past decade, Fisher & Paykel Healthcare's EBITDA Margin % has ranged from 20.94 to 51.11. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #51 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 6.2%.
Is Fisher & Paykel Healthcare's EBITDA Margin % too high?
Fisher & Paykel Healthcare's current EBITDA Margin % of 36.12% is near median its 10-year median of 33.48. Over the past 10 years, this metric has ranged from a low of 20.94 to a high of 51.11. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Fisher & Paykel Healthcare's value of 36.12% is 383.2% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #51 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #51 out of 816 companies for EBITDA Margin %. This places Fisher & Paykel Healthcare in the top 6% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Fisher & Paykel Healthcare's value of 36.12% is 383.2% above this benchmark. Historically, Fisher & Paykel Healthcare's own EBITDA Margin % has ranged from 20.94 to 51.11 over the past decade. While the company's 10-year median is 33.48 vs. the industry median of 7.48, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current EBITDA Margin % of 36.12% is 383.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current EBITDA Margin % is 36.12%, which is near median its own 10-year median of 33.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Fisher & Paykel Healthcare (FRA:FPLB) has a current EBITDA Margin % of 36.12%. The stock's GF Value™ is €21.23, compared to a current price of €18.90 — trading 11% below its estimated fair value. The current EBITDA Margin % is 36.12%, which is near median its 10-year median of 33.48 and 383.2% above the Medical Devices & Instruments industry median of 7.48. Fisher & Paykel Healthcare's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Fisher & Paykel Healthcare (FRA:FPLB), the current EBITDA Margin % is 36.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (FRA:FPLB) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of €18.90 is trading 11% below its estimated GF Value™ of €21.23.
Key valuation signals for FRA:FPLB:
EBITDA Margin %: 36.12% (near median its 10-year median of 33.48)
GF Value™: €21.23 vs. price of €18.90 (11% below fair value)
Industry Position: 383.2% above the Medical Devices & Instruments median (#51 of 816)
No single metric tells the full story. See the FRA:FPLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
91GF Score
Get the complete analysis for FRA:FPLB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FPLB has been successfully added to your 
